VRN-01 is under clinical development by Voronoi Group and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VRN-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VRN-01 overview

VRN-01 is under development for the treatment of glioblastoma multiforme, gemcitabine-resistant pancreatic cancer and triple negative breast cancer. The drug candidate development is based on voronoi kinase platform technology. The therapeutic candidate acts by targeting LRRK2.

Voronoi Group overview

Voronoi Group (Voronoi) is a Korean company that develops new drugs for the treatment of rare and intractable diseases. The company carries out the development of target protein degraders (TPDs) and kinase inhibitors. Its pipeline includes VRN01, VRN06, VRN07, VRN08, VRN09 and others .Voronoi is involved in the technology transfer of new drug candidates prior to electroclinical clinical trials by using AI platform integrating molecular model and structural biology. The company operates in Korea. Voronoi is headquartred in Incheon Republic of Korea.

For a complete picture of VRN-01’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.